

# CITATION REPORT

List of articles citing

**mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm**

**DOI: 10.1002/ijc.29887**

**International Journal of Cancer, 2016, 138, 2312-21.**

**Source:** <https://exaly.com/paper-pdf/63405220/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 69 | Safety of mTOR inhibitors in breast cancer. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 1075-85   | 4.1  | 6         |
| 68 | Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials. <i>Future Oncology</i> , <b>2016</b> , 12, 1529-39   | 3.6  | 6         |
| 67 | Targeting the Mammalian Target of Rapamycin in Lung Cancer. <i>American Journal of the Medical Sciences</i> , <b>2016</b> , 352, 507-516   | 2.2  | 16        |
| 66 | Drugs That Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs. <i>Side Effects of Drugs Annual</i> , <b>2016</b> , 38, 407-424  | 0.2  |           |
| 65 | Phase I Study of Apatolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2874-84 | 12.9 | 75        |
| 64 | Management of Adverse Effects by Molecular Targeted Therapy and Immunotherapy. <b>2017</b> , 253-267   |      |           |
| 63 | A screening strategy for the discovery of drugs that reduce C/EBP $\beta$ translation with potential calorie restriction mimetic properties. <i>Scientific Reports</i> , <b>2017</b> , 7, 42603                                    | 4.9  | 8         |
| 62 | mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression. <i>Journal of Clinical Pathology</i> , <b>2017</b> , 70, 410-416                            | 3.9  | 14        |
| 61 | Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. <i>Oncologist</i> , <b>2017</b> , 22, 648-654     | 5.7  | 8         |
| 60 | Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2017</b> , 81, 9-16   | 7.5  | 10        |
| 59 | Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 525-536                      | 1.1  |           |
| 58 | Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?. <i>Drug Safety</i> , <b>2017</b> , 40, 211-228   | 5.1  | 7         |
| 57 | Sirolimus for the treatment of lymphangiomyomatosis. <i>Expert Opinion on Orphan Drugs</i> , <b>2017</b> , 5, 907-921  | 1.1  | 5         |
| 56 | A case of delayed exacerbation of interstitial lung disease after discontinuation of temsirolimus. <i>Respiratory Medicine Case Reports</i> , <b>2017</b> , 22, 158-163  | 1.2  | 3         |
| 55 | Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. <i>Transplant Infectious Disease</i> , <b>2017</b> , 19, e12751          | 2.7  | 53        |
| 54 | Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies. <i>Radiographics</i> , <b>2017</b> , 37, 1461-1482  | 5.4  | 14        |
| 53 | Use of Everolimus in Liver Transplantation: Recommendations From a Working Group. <i>Transplantation</i> , <b>2017</b> , 101, 239-251  | 1.8  | 39        |

|    |  |     |    |
|----|--|-----|----|
| 52 | Drugs That Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs. <i>Side Effects of Drugs Annual</i> , <b>2017</b> , 389-406  | 0.2 | 1  |
| 51 | Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology. <i>Cancer Investigation</i> , <b>2018</b> , 36, 37-58  | 2.1 | 12 |
| 50 | Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma. <i>Medical Oncology</i> , <b>2018</b> , 35, 16  | 3.7 | 6  |
| 49 | Life-Threatening Everolimus-Associated Pneumonitis: A Case Report and a Review of the Literature. <i>Transplantation Proceedings</i> , <b>2018</b> , 50, 933-938   | 1.1 | 7  |
| 48 | Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e151-e161   | 4.9 | 31 |
| 47 | Multidisciplinary management of refractory insulinomas. <i>Clinical Endocrinology</i> , <b>2018</b> , 88, 615-624  | 3.4 | 19 |
| 46 | Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. <i>Annals of Gastroenterology</i> , <b>2018</b> , 31, 140-150   | 2.2 | 5  |
| 45 | Everolimus-induced pulmonary toxicity: Findings on 18F-FDG PET/CT imaging. <i>Medicine (United States)</i> , <b>2018</b> , 97, e12518  | 1.8 | 4  |
| 44 | Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 342-349   | 2.2 | 70 |
| 43 | [Analysis of Time-to-onset and Onset-pattern of Interstitial Lung Disease after the Administration of Monoclonal Antibody Agents]. <i>Yakugaku Zasshi</i> , <b>2018</b> , 138, 1587-1594   | 0   | 6  |
| 42 | Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients. <i>Hematological Oncology</i> , <b>2018</b> , 36, 779-785  | 1.3 | 2  |
| 41 | mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , <b>2018</b> , 85-105  | 0.3 |    |
| 40 | Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. <i>Targeted Oncology</i> , <b>2019</b> , 14, 441-451  | 5   | 5  |
| 39 | A Fatal Case of Life-Threatening Interstitial Pneumonitis Induced by Everolimus for Metastatic Renal Cell Carcinoma: A Comment about the Increased Risk of Interstitial Lung Disease in Japanese. <i>Case Reports in Urology</i> , <b>2019</b> , 2019, 2703871 | 0.5 |    |
| 38 | Analyses of alveolar epithelial injury via lipid-related stress in mammalian target of rapamycin inhibitor-induced lung disease. <i>Laboratory Investigation</i> , <b>2019</b> , 99, 853-865   | 5.9 | 2  |
| 37 | mTOR Inhibitors. <b>2019</b> , 261-282   |     |    |
| 36 | The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis. <i>Medicina (Lithuania)</i> , <b>2020</b> , 56,  | 3.1 | 2  |
| 35 | Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs. <i>Acta Radiologica</i> , <b>2021</b> , 62, 1006-1015   | 2   | 0  |

|    |  |     |    |
|----|--|-----|----|
| 34 | Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event. <i>Current Problems in Cancer Case Reports</i> , <b>2020</b> , 2, 100023   | 0.3 |    |
| 33 | Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF non-small cell lung cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 132, 211-223   | 7.5 | 23 |
| 32 | Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study. <i>Japanese Journal of Clinical Oncology</i> , <b>2020</b> , 50, 940-947 | 2.8 | 2  |
| 31 | Sirolimus-induced interstitial lung disease and resolution after conversion to everolimus. <i>Respiratory Medicine Case Reports</i> , <b>2020</b> , 30, 101109   | 1.2 | 1  |
| 30 | Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 183, 23-39  | 4.4 | 24 |
| 29 | Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1836-1845   | 4.3 | 2  |
| 28 | Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study. <i>Clinical Imaging</i> , <b>2021</b> , 71, 29-33  | 2.7 | 1  |
| 27 | Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane. <i>International Immunopharmacology</i> , <b>2021</b> , 93, 107404  | 5.8 | 0  |
| 26 | Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. <i>Investigational New Drugs</i> , <b>2021</b> , 39, 1707-1715   | 4.3 | 2  |
| 25 | A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2021</b> ,   | 3   | 1  |
| 24 | mTOR Inhibition Promotes Pneumonitis through Inducing Endothelial Contraction and Hyperpermeability. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2021</b> , 65, 646-657   | 5.7 | 0  |
| 23 | Fungal pneumonia in kidney transplant recipients. <i>Respiratory Medicine</i> , <b>2021</b> , 185, 106492  | 4.6 | 0  |
| 22 | Drugs associated with drug-induced interstitial lung diseases. <i>Kachestvennaya Klinicheskaya Praktika</i> , <b>2021</b> , 39-51  | 0.4 |    |
| 21 | From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data. <i>Journal of Chemotherapy</i> , <b>2021</b> , 1-6  | 2.3 |    |
| 20 | Pulmonary Complications of Lung Cancer Therapies. <b>2022</b> , 931-949  |     |    |
| 19 | pneumonia in a kidney transplant recipient - dose-dependent decrease of phagocytic activity as a potential mechanism for everolimus pulmonary toxicity. <i>Central-European Journal of Immunology</i> , <b>2021</b> , 46, 405-417  | 1.6 |    |
| 18 | Drug-related pneumonitis with radiographic hypersensitivity pneumonitis pattern: Three case series. <i>Respiratory Medicine Case Reports</i> , <b>2021</b> , 34, 101498  | 1.2 | 0  |
| 17 | Unveiling changes in the landscape of patient populations in cancer early drug development. <i>Oncotarget</i> , <b>2017</b> , 8, 14158-14172   | 3.3 | 7  |

|    |  |      |    |
|----|--|------|----|
| 16 | Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 17652-64 | 3.3  | 40 |
| 15 | Pneumonitis After Precision Oncology Therapies: A Concise Review. <i>Journal of Immunotherapy and Precision Oncology</i> , <b>2018</b> , 1, 26-37                      | 0.6  | 3  |
| 14 | Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. <i>JAMA Oncology</i> , <b>2021</b> ,   | 13.4 | 9  |
| 13 | Rapalogs Target the Endothelium to Set the Stage for Acute Lung Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2021</b> , 65, 576-577  | 5.7  |    |
| 12 | Types of Cancer. <b>2019</b> , 53-150  |      | 0  |
| 11 | Pharmacology and pharmacovigilance of protein kinase inhibitors.. <i>Therapie</i> , <b>2021</b> ,  | 3.8  | 1  |
| 10 | STAT3 polymorphism associates with mTOR inhibitor-induced interstitial lung disease in patients with renal cell carcinoma.. <i>Oncology Research</i> , <b>2022</b> ,   | 4.8  |    |
| 9  | Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. <i>Oncologist</i> ,                           | 5.7  | 2  |
| 8  | Drug-induced interstitial lung disease.. <i>European Respiratory Journal</i> , <b>2022</b> ,   | 13.6 | 3  |
| 7  | Pulmonary toxicity of mTOR inhibitors. Comparisons of two populations: Solid organ recipients and cancer patients. <i>Therapie</i> , <b>2022</b> ,                     | 3.8  |    |
| 6  | Concomitant Radiation and Systemic Therapy in the Adjuvant and Metastatic Setting. <b>2022</b> , 421-434   |      | 0  |
| 5  | Perspectives of vitamin C upregulating regulatory T cells in the era of thrombopoietin receptor agonists for immune thrombocytopenia. <b>2022</b> , 2,                 |      | 0  |
| 4  | TAPO in first-line osimertinib therapy and continuation of osimertinib.  |      | 0  |
| 3  | Drug-Induced Interstitial Lung Diseases. <b>2023</b> , 43, 341-357   |      | 0  |
| 2  | Exploring the Link Between Mtor Inhibitors and Interstitial Lung Diseases: A Disproportionality Analysis Using Fda Adverse Event Reporting System Database.            |      | 0  |
| 1  | Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. <b>2023</b> , 43, 1-12   |      | 0  |